Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APsulloc 331261
- Development stage
- Unknown
- Lead developer
- Amorepacific Corporation
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
APsulloc 331261 (GTB1) is a live biotherapeutic probiotic strain of *Lactiplantibacillus plantarum* (formerly *Lactobacillus plantarum*) isolated from green tea leaves by the South Korean company AMOREPACIFIC. It is primarily being investigated for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D), where it has reached Phase 2 clinical testing. The strain's mechanism of action involves the modulation of gut microbiota, enhancement of short-chain fatty acid production (specifically butyrate), and regulation of the Th1/Th2 cytokine balance. Preclinical studies have also demonstrated its potential in treating atopic dermatitis, obesity, and allergic airway inflammation by reducing epidermal thickness, mast cell infiltration, and mucin hypersecretion.
- Brand names
- GTB1GTB-1GTB 1
- Other names
- Lactiplantibacillus plantarum APsulloc 331261Lactobacillus plantarum APsulloc 331261
Beyond the preview
Go deeper on APsulloc 331261.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APsulloc 331261.